Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.

Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.

MANAGEMENT TEAM
Anna Protopapas
President and Chief Executive Officer

Ms. Protopapas joined Mersana in March 2015, bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business. Ms. Protopapas also served as the Executive Vice President of Global Business Development for Takeda Pharmaceuticals where she was responsible for global acquisitions, partnering, licensing and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She was instrumental in the sale of Millennium to Takeda for $8.8 billion. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.

Donald A. Bergstrom
M.D., Ph.D.
Chief Medical Officer

Dr. Bergstrom joined Mersana in January 2014, bringing a decade of industry experience in translational medicine and drug development. Prior to Mersana, Dr. Bergstrom spent four years as Associate Vice President and Global Head of Translational and Experimental Medicine at Sanofi Oncology, where he built a global team of laboratory and clinical scientists focused on defining and executing scientifically rigorous early development strategies. Dr. Bergstrom represented Sanofi in the governance of a number of collaborations with academic and industry partners. Prior to Sanofi, Dr. Bergstrom spent six years at Merck Research Labs in roles of increasing responsibility in the Clinical Molecular Profiling, Oncology Clinical Research and Experimental Medicine Oncology groups. Dr. Bergstrom completed his M.D. and residency at the University of Washington and his Ph.D. and post-doctoral training at the Fred Hutchinson Cancer Research Center.

Wayne Foster
C.P.A.
Vice President of Finance

Mr. Foster joined Mersana in February 2012, bringing more than 20 years of financial management and public accounting experience. Prior to Mersana, he served for nine years as Senior Director of Finance at Tolerx, where he was responsible for a wide variety of finance functions during a period of significant growth for the company.. He spent nine years as a Senior Manager at Arthur Andersen, where he specialized in emerging life science and technology companies. He earned his B.B.A. in Accounting from the University of Massachusetts Amherst.

Eva M. Jack
Chief Business Officer

Ms. Jack joined Mersana in November 2013, bringing a wealth of business development and financial experience in the biotech industry. Prior to Mersana, she served as an advisor to biotech companies and investors on business and financing strategies. From 2010 to 2012, she served as Chief Business Officer of Pulmatrix. She also spent six years at MedImmune, the worldwide biologics unit of AstraZeneca, as Managing Director of MedImmune Ventures, overseeing investments in private biotechnology companies, and as a Director in MedImmune’s Business Development group. Earlier in her career, Ms. Jack held a variety of positions at Intel Corp. in venture investments, corporate strategy and public policy. Ms. Jack received a B.A. from the University of Virginia and a master’s in health sciences from The Johns Hopkins University.  Additionally, she is a volunteer puppy raiser for Canine Companions for Independence®, a non-profit organization that enhances the lives of people with disabilities by providing highly trained assistance dogs.

Timothy B. Lowinger
Ph.D.
Chief Scientific Officer

Dr. Lowinger joined Mersana in 2008, bringing nearly 15 years of global scientific leadership and drug discovery experience in the pharmaceutical and biotech industries. Over the course of his career at Bayer Pharmaceuticals in the US, Japan and Germany, he contributed to the discovery of more than 15 preclinical and clinical drug candidates in the areas of oncology, asthma, inflammation, virology, obesity and diabetes. Most notably, Dr. Lowinger is a co-inventor of the pioneering anti-angiogenic agent Nexavar (sorafenib), approved for the treatment of renal and hepatocellular cancer, as well as Stivarga (regorafenib), approved for the treatment of metastatic colorectal cancer. Dr. Lowinger has published more than 40 scientific papers and is a co-inventor on more than 40 patents. He has a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia and was a Merck Postdoctoral Fellow at the Ohio State University in the lab of Professor Leo A. Paquette. He currently serves on the Scientific Advisory Board of Keystone Symposia.

Peter U. Park
Ph.D.
Vice President of Biology

Dr. Park joined Mersana in January 2013, bringing significant experience in the discovery and development of antibody and antibody-drug conjugate therapies. Before joining Mersana, he was a co-founder and CEO of Habgen, a startup focused on immuno-oncology antibody therapeutics. Prior to that, Dr. Park spent 10 years in various roles at ImmunoGen, most recently as Senior Director of Discovery Research. In this role, he managed the discovery research portfolio for the development of novel monoclonal antibody and antibody drug conjugates for oncology, co-inventing and advancing three compounds that are currently in clinical testing. Additionally, he oversaw ImmunoGen’s research collaboration with Sanofi. He started at ImmunoGen as a research scientist who began and led the development of a novel anti-CD38 antibody SAR650984 for multiple myeloma, which was licensed to Sanofi and is currently in Phase 2 testing. Dr. Park is a co-inventor on more than 10 patents and has contributed to numerous scientific publications. He earned his B.S. and Ph.D. in Biology from the Massachusetts Institute of Technology.

BOARD OF DIRECTORS
David Mott
General Partner, New Enterprise Associates

Mr. Mott joined Mersana’s board as Chairman in July 2012. He is a General Partner at New Enterprise Associates, where he leads the healthcare investing practice. Before joining NEA, he spent 16 years at MedImmune in roles of increasing responsibility, including Chief Operating Officer, Chief Financial Officer and CEO, building the company from a venture-backed startup into one of the top five biotechnology companies in the world, He led the sale of MedImmune to AstraZeneca in 2007 for $15.6 billion, and at the time of his departure in 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Mr. Mott is also Chairman of 3-V Biosciences, Cydan, Prosensa, TESARO and Zyngenia and a director of Ardelyx, Edimer Pharmaceuticals and Epizyme. He received his B.A. from Dartmouth College.

Thomas R. Beck
M.D.
Executive Partner, Fidelity Biosciences

Dr. Beck is an Executive Partner at Fidelity Biosciences. Before joining Fidelity in 2007, he served as President and Chief Operating Officer at Dyax Corp. During his more than 30-year career in the pharmaceutical and biotech industries, Dr. Beck has held a number of leadership positions at companies, including UCB Pharma, CytoMed and Enzytech. He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development. Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. Dr. Beck also serves on the Board of Directors of NeuroTherapeutics Pharma and Vicept Therapeutics. He received his B.S. degree from Yale University and his M.D. from Cornell University.

Elaine V. Jones
Ph.D.
Executive Director, Pfizer Venture Investments

Dr. Jones is an Executive Director at Pfizer Venture Investments. She is responsible for making and managing venture investments for Pfizer and currently manages its investments in Aquinox Pharmaceuticals, Flexion Therapeutics, Merus B.V. and NeuroTherapeutics Pharma. Dr. Jones brings a decade of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development. Prior to joining Pfizer, Dr. Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund. Before that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.

Sara Nayeem
M.D.
Principal, New Enterprise Associates

Dr. Nayeem is a Principal at New Enterprise Associates, where she focuses on investments in biopharmaceutical companies. She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has been involved in NEA’s investments in 3-V Biosciences and Prosensa. She also assists with management of several of NEA's publicly traded portfolio companies. Prior to joining NEA in 2009, Dr. Nayeem was an Associate with Merrill Lynch’s Global Healthcare Group, advising biotechnology, pharmaceutical and medical device companies on mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. Dr. Nayeem received her AB in Biological Sciences from Harvard University and her M.D. and M.B.A. from Yale University.

Anna Protopapas
Chief Executive Officer

Ms. Protopapas joined Mersana in February 2015, bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business, and a member of Takeda’s Executive Committee. In four years as an executive officer at Takeda, Ms. Protopapas served in various roles of increasing responsibility, including as the Executive Vice President of Global Business Development responsible for global acquisitions, partnering, licensing and venture investing. In this role, she was instrumental in developing and executing a business plan to globalize Takeda and led the company’s $12 billion acquisition of Nycomed. Prior to Takeda’s acquisition of Millennium in 2008, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.